- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03116412
A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma (TRIM)
April 17, 2019 updated by: Uppsala University
A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma
It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival.
Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure it is an important question to address.
With the introduction of effective medical treatments for malignant melanoma patients, there is a tendency to introduce radiological assessments despite the lack of evidence.
Study Overview
Detailed Description
The patients are randomized 1:1 to routine follow up for 3 years with regular doctors´ appointments according to national guidelines and the same follow up but with the addition of whole body CT or Positron Emission Tomography (PET) scans and blood tests.
Study Type
Interventional
Enrollment (Anticipated)
1300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Boras, Sweden
- Recruiting
- Södra Älvsborgs Sjukhus
-
Contact:
- Janusz Ratajczak, MD
- Phone Number: +46 6161000
- Email: janusz.ratajczak@vgregion.se
-
Principal Investigator:
- Lars Larsson
-
Eskilstuna, Sweden
- Recruiting
- Mälarsjukhuset Eskilstuna
-
Principal Investigator:
- Antonis Valachis
-
Contact:
- Agneta Nordén
- Phone Number: +4616103343
- Email: agneta.norden@dll.se
-
Falun, Sweden
- Recruiting
- Falu Lasarett
-
Contact:
- Anna-Lena Fahlberg
- Phone Number: +46708249653
- Email: anna-lena.fahlberg@ltdalarna.se
-
Principal Investigator:
- Ulf Dyrke
-
Gavle, Sweden
- Recruiting
- Gavle Sjukhus
-
Contact:
- Lena Persson
- Phone Number: +4626155423
- Email: lena.g.persson@regiongavleborg.se
-
Principal Investigator:
- Olga val Munos
-
Gothenburg, Sweden
- Recruiting
- Department of surgery, Sahlgrenska University Hospital
-
Contact:
- Therese Bengtsson
- Phone Number: +46313428454
- Email: Therese.Bengtsson@vgregion.se
-
Principal Investigator:
- Roger Olofsson Bagge
-
Helsingborg, Sweden
- Recruiting
- Helsingborgs lasarett
-
Contact:
- Kerstin Reistad
- Phone Number: +46424063762
- Email: kerstin.reistad@skane.se
-
Principal Investigator:
- Katrin Lange-Norström
-
Jonkoping, Sweden
- Recruiting
- Länssjukhuset Ryhov
-
Contact:
- Therese Karlsson
- Phone Number: +46102425962
- Email: therese.i.karlsson@rjl.se
-
Principal Investigator:
- Dimitrios Papantoniou
-
Kalmar, Sweden
- Not yet recruiting
- Länssjukhuset i Kalmar
-
Principal Investigator:
- Lars Gustavsson Wallander
-
Karlstad, Sweden
- Recruiting
- Centralsjukhuset i Karlstad
-
Contact:
- Eva Sätherberg
- Phone Number: +4654615971
- Email: eva.satherberg@liv.se
-
Principal Investigator:
- Lars Ohlsson
-
Linkoping, Sweden
- Recruiting
- Linkoping University Hospital
-
Contact:
- Kerstin Hultgren
- Phone Number: +46101031961
- Email: kerstin.hultgren@regionostergotland.se
-
Contact:
- Madeleine Rasic
- Phone Number: +46101035879
-
Principal Investigator:
- Nils Elander
-
Luleå, Sweden
- Not yet recruiting
- Sunderby Sjukhus
-
Contact:
- Lisa Eskilsson
- Phone Number: +46920280063
- Email: lisa.eskilsson@norrbotten.se
-
Principal Investigator:
- Fredrik Riström
-
Lund, Sweden
- Recruiting
- Skane University Hospital
-
Contact:
- Gunilla Berggren
- Phone Number: +4646172013
- Email: gunilla.GB.berggren@skane.se
-
Principal Investigator:
- Karolin Isaksson
-
Orebro, Sweden
- Recruiting
- Orebro University Hospital
-
Contact:
- Sofia Axelsson
- Phone Number: +46196022719
- Email: forskningsskoterska.onk.uso@regionorebrolan.se
-
Principal Investigator:
- Frida Jakobsson
-
Skovde, Sweden
- Recruiting
- Skaraborgs sjukhus Skövde
-
Contact:
- Charlotte Sparring
- Phone Number: +46500432114
- Email: charlotte.sparring@vgregion.se
-
Principal Investigator:
- Charlotte Sparring
-
Stockholm, Sweden
- Recruiting
- Karolinska University Hospital
-
Contact:
- Leia Ollmar
- Phone Number: +46851779694
- Email: leia.ollmar@sll.se
-
Principal Investigator:
- Johan Hansson
-
Sundsvall, Sweden
- Recruiting
- Länssjukhuset Sundsvall
-
Contact:
- Carina Eliasson
- Phone Number: +46730315197
- Email: carina.eliasson@lvn.se
-
Principal Investigator:
- Petra Flygare
-
Uddevalla, Sweden
- Recruiting
- Uddevalla Sjukhus
-
Contact:
- Annett Gustafsson
- Phone Number: +46104353371
- Email: annett.gustafsson@vgregion.se
-
Principal Investigator:
- Carin Wångblad
-
Umea, Sweden
- Recruiting
- Umeå University Hospital
-
Contact:
- Agneta Karhu
- Phone Number: +46907850000
- Email: agneta.karhu@vll.se
-
Principal Investigator:
- Malin Jansson
-
Uppsala, Sweden
- Recruiting
- Akademiska Sjukhuset
-
Contact:
- Camilla Taavo
- Phone Number: +46186111034
- Email: camilla.taavo@akademiska.se
-
Principal Investigator:
- Gustav Ullenhag
-
Vasteras, Sweden
- Recruiting
- Västmanlands sjukhus Västerås
-
Contact:
- Lisa Hultberg
- Phone Number: +4621173000
- Email: liselotte.hultberg@regionvastmanland.se
-
Principal Investigator:
- Cecilia Nilsson
-
Visby, Sweden
- Recruiting
- Visby lasarett
-
Contact:
- Marie Boberg
- Phone Number: +46498269000
- Email: marie.boberg01@gotland.se
-
Principal Investigator:
- Agneta Nordin Danfors
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age.
- Radical surgery for Cutaneous Malignant Melanoma (CMM) stage IIb-c and III.
- Sufficient renal function for i.v. contrast scannings.
Exclusion Criteria:
- The patient is assessed as unfit to receive treatment in the case of recurrence.
- Life-expectancy less than 2 years due to concurrent disease (e.g., cardiac disease, terminal multiple sclerosis, liver cirrhosis).
- Inability to provide informed consent or refusal to do so.
- Inability to comply with the control or intense follow-up program.
- Participation in other clinical trials interfering with the control-program.
- Existing or previous malignancies within the past 5 years (except for in situ breast and cervical cancer, melanoma in situ and non-melanoma skin cancer).
- Pregnancy or currently planned pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Routine follow up
Follow up according to national guidelines.
|
|
Experimental: Radiological assessments
Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
|
Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: At 5 years
|
Measured from date of inclusion
|
At 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life/QLQ30
Time Frame: During the 3 year intervention period
|
Question of Life Questionnaire (QLQ) 30
|
During the 3 year intervention period
|
Quality of life/HAD
Time Frame: During the 3 year intervention period
|
Hospital, Anxiety and Depression (HAD) scale
|
During the 3 year intervention period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gustav Ullenhag, associate professor, Uppsala University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2017
Primary Completion (Anticipated)
December 31, 2026
Study Completion (Anticipated)
December 31, 2026
Study Registration Dates
First Submitted
March 14, 2017
First Submitted That Met QC Criteria
April 11, 2017
First Posted (Actual)
April 17, 2017
Study Record Updates
Last Update Posted (Actual)
April 18, 2019
Last Update Submitted That Met QC Criteria
April 17, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRIM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsKorea, Republic of, Brazil, United States, Canada, Cyprus
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsSpain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
Clinical Trials on CT or PET scans
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
London Health Sciences CentreCompleted
-
Memorial Sloan Kettering Cancer CenterCompletedCD34 Selected Peripheral Blood Stem Cell GraftUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnHistologically-confirmed MalignanciesUnited States
-
prof. dr. Koen Van LaereUniversitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Ghent; Fund...Not yet recruitingParkinson Disease | Alzheimer Disease | Dementia With Lewy Bodies | MSA - Multiple System AtrophyBelgium
-
Memorial Sloan Kettering Cancer CenterRecruitingHead and Neck CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedBrain CancerUnited States
-
University Hospital, EssenCompleted
-
University Hospital Bispebjerg and FrederiksbergCompletedPatellofemoral Pain Syndrome | Anterior Knee Pain SyndromeDenmark
-
NYU Langone HealthCompletedNasopharyngeal CancerUnited States